Breast cancer is the first in incidence and the second in death among all solid tumors occurring in women. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment.
NKA is a significant integral membrane protein. NKA's main function is the creation and maintenance of electrochemical gradients for sodium and potassium ions in the living cell. These gradients have critical importance for control of cell volume, osmolarity and resting potential 7, 8 . The minimal functional NKA consists of two associated alpha-and beta-subunits. The catalytic alpha-subunit is responsible for conversion of ATP energy to transport of Na + and K + across cell membranes and has ATP and cardiac glycosides binding sites. It may be present in human tissues in four different isoforms (α1, α2, α3, α4 -found only in testicles). The beta-subunit is responsible for delivery and insertion of alpha one in cell membranes and has three distinct isoforms in humans (β1, β2, β3) [8] [9] [10] . NKA subunits are variably expressed in different human tissues 11 . Changes in the relative expression between different isoforms are associated with a number of pathological processes including malignant transformation 12, 13 . Both down-and up-regulation of alpha-and beta-subunits were shown in solid tumors of different origin [14] [15] [16] [17] [18] [19] .
In the present study, we analyzed public breast cancer expression profiles made using Affymetrix Human Genome U133 Plus 2.0 Array (NCBI GEO database 20 , accession GSE65194) for the expression of alpha subunits of NKA. We found abnormalities in ATP1A1 (coding α1-subunit) and ATP1A2 (coding α2-subunit) expression (Table 1) in breast cancer samples relative to their expression in normal breast tissue. ATP1A1 was overexpressed approximately 1.5 times in all groups of breast cancer samples (p<0.05). Coincidently, ATP1A2 expression decreased by more than 2 times (p<0.05). There were no differences observed in the expression of ATP1A3 (coding α3-subunit).
Methods
Preanalytical procedures consisted of a robust multichip analysis (RMA) algorithm 21 , including background correction, probe set signal integration, and quantile normalization. For this purpose, we used Expression Console 1.4 software (Affymetrix, Inc. USA). We utilized Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) to analyze the obtained CHP files and to detect differentially expressed genes using one-way between subjects ANOVA. Array data for 41 triple negative samples (TNBC group), 30 Her2-positive (Her2 group), 30 Luminal B (Lum B group), 29 Luminal A (Lum A group) breast cancer samples and 11 normal breast tissue samples were investigated.
Conclusions
Using a public microarray dataset we found abnormalities in the expression of ATP1A1 and ATP1A2 in breast cancer samples. This may correlate with digitalis anticancer activity, but requires additional research. We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer.
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